U.S. Markets close in 3 hrs 15 mins
  • S&P 500

    4,573.06
    +6.58 (+0.14%)
     
  • Dow 30

    35,762.88
    +21.73 (+0.06%)
     
  • Nasdaq

    15,219.36
    -7.35 (-0.05%)
     
  • Russell 2000

    2,307.11
    -5.53 (-0.24%)
     
  • Gold

    1,792.40
    -14.40 (-0.80%)
     
  • EUR/USD

    1.1593
    -0.0022 (-0.1855%)
     
  • 10-Yr Bond

    1.6260
    -0.0090 (-0.55%)
     
  • Vix

    16.14
    +0.90 (+5.91%)
     
  • GBP/USD

    1.3764
    -0.0005 (-0.0330%)
     
  • USD/JPY

    114.1530
    +0.4540 (+0.3993%)
     
  • BTC-USD

    62,202.82
    -1,367.05 (-2.15%)
     
  • CMC Crypto 200

    1,494.39
    -10.76 (-0.71%)
     
  • FTSE 100

    7,277.62
    +54.80 (+0.76%)
     
  • Nikkei 225

    29,106.01
    +505.60 (+1.77%)
     

Infinity to Present at the Oppenheimer & Co. Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that management will present at the Oppenheimer & Co. Annual Healthcare Conference which is being held Tuesday, March 16th – Thursday, March 18th, 2021. Presentation details are as follows:

Oppenheimer & Co. Annual Healthcare Conference Company Presentation:

Date:

Wednesday, March 17

Time:

1:10 pm Eastern Time

Webcast:

https://wsw.com/webcast/oppenheimer9/infi/2701886

The webcast of the presentation can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and eganelisib

Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005164/en/

Contacts

Investor Relations:
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com